ARYA Sciences Acquisition Corp V
ARYE
NASDAQ Capital Market10.36
USD
-0.02
- -
CIK
0001852432
ISIN
KYG316581001
CUSIP
G31658100
Return %
Stock
S&P500
1Y
6.04
26.84
3Y
3.60
77.03
5Y
3.60
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam Leo Stone
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 51 Astor Place New York City NY United States of America 10003
- IPO Date
- Jul 13, 2021
- CIK
- 0001852432
- Similar Companies
- Business
- ARYA Sciences Acquisition Corp V is a special purpose acquisition company (SPAC) incorporated in 2021 and headquartered in New York, New York. The company is formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations primarily targeting the healthcare and healthcare-related industries. As a blank check company, ARYA Sciences Acquisition Corp V does not manufacture or sell products directly, nor has it commenced any operations or generated revenues. Its core focus is identifying and acquiring businesses in the life sciences and medical technology sectors, particularly in North America and Europe. In terms of recent major changes, ARYA Sciences Acquisition Corp V announced that it would redeem its Class A ordinary shares and will not consummate an initial business combination, effectively liquidating the company and returning the cash held in trust to its shareholders as of mid-2023. This decision marked a significant operational change, diverging from the initial intent to pursue business combinations and indicating that the company will cease further acquisition activities. ARYA Sciences Acquisition Corp V operates within the investment holding company sector, with an emphasis on healthcare-related mergers and acquisitions rather than direct product or service offerings. It is sponsored by an affiliate of Perceptive Advisors and has focused on target businesses with valuations typically ranging from $300 million to $500 million or higher. The company has no subsidiaries as it functions primarily as an acquisition vehicle, and its strategic shifts include the recent cessation of its share combination efforts and winding down operations. Given these points, ARYA Sciences Acquisition Corp V serves as a financial vehicle specialized in healthcare sector acquisitions but has recently ceased its merger activities with no products or services apart from its investment pursuits. Its most recent corporate action involved the redemption of public shares and cessation of business combination plans in 2023.
ARYA Sciences Acquisition Corp V will redeem its Class A Ordinary Shares and will not consummate an initial business combination